BR112022005039A2 - Tratamento de hepatite alcoólica - Google Patents

Tratamento de hepatite alcoólica

Info

Publication number
BR112022005039A2
BR112022005039A2 BR112022005039A BR112022005039A BR112022005039A2 BR 112022005039 A2 BR112022005039 A2 BR 112022005039A2 BR 112022005039 A BR112022005039 A BR 112022005039A BR 112022005039 A BR112022005039 A BR 112022005039A BR 112022005039 A2 BR112022005039 A2 BR 112022005039A2
Authority
BR
Brazil
Prior art keywords
treatment
alcoholic hepatitis
methods
hepatitis
25hc3s
Prior art date
Application number
BR112022005039A
Other languages
English (en)
Inventor
E Brown James
Terrence Blaschke
Weiqi Lin
Original Assignee
Durect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Durect Corp filed Critical Durect Corp
Publication of BR112022005039A2 publication Critical patent/BR112022005039A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

tratamento de hepatite alcoólica. a presente invenção refere-se a métodos para tratar hepatite alcoólica (ah) são fornecidos. por exemplo, os métodos podem compreender administrar 5-colesten-3,25-diol, 3-sulfato (25hc3s) ou um sal do mesmo.
BR112022005039A 2019-09-30 2020-09-29 Tratamento de hepatite alcoólica BR112022005039A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962908465P 2019-09-30 2019-09-30
US201962933206P 2019-11-08 2019-11-08
US202063060564P 2020-08-03 2020-08-03
US202063081208P 2020-09-21 2020-09-21
PCT/US2020/053315 WO2021067297A1 (en) 2019-09-30 2020-09-29 Treatment of alcoholic hepatitis

Publications (1)

Publication Number Publication Date
BR112022005039A2 true BR112022005039A2 (pt) 2022-06-21

Family

ID=75336475

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022005039A BR112022005039A2 (pt) 2019-09-30 2020-09-29 Tratamento de hepatite alcoólica

Country Status (12)

Country Link
US (1) US20220378802A1 (pt)
EP (1) EP4037650A4 (pt)
JP (1) JP2022549621A (pt)
KR (1) KR20220075329A (pt)
CN (1) CN114555044A (pt)
AU (1) AU2020357818A1 (pt)
BR (1) BR112022005039A2 (pt)
CA (1) CA3155422A1 (pt)
IL (1) IL291287A (pt)
MX (1) MX2022003778A (pt)
TW (1) TW202128184A (pt)
WO (1) WO2021067297A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024097247A1 (en) * 2022-10-31 2024-05-10 Intercept Pharmaceuticals, Inc. Uses of farnesoid x receptor agonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047022A1 (en) * 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
US8399441B2 (en) 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
US9034859B2 (en) * 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
MX357046B (es) * 2012-04-12 2018-06-22 Univ Virginia Commonwealth Un metabolito de colesterol novedoso, 5-colesteno-3b-25-diol disulfato (25hcds) para terapia de trastornos metabolicos, hiperlipidemia, diabetes, enfermedad de higado graso y aterosclerosis.
KR20240051283A (ko) * 2013-12-24 2024-04-19 버지니아 커먼웰스 유니버시티 산소첨가된 콜레스테롤 술페이트 (ocs) 의 용도
MX2019001327A (es) * 2016-08-02 2019-07-08 Durect Corp Composiciones que comprenden sulfato de colesterol oxigenado y por lo menos uno de poli-alquilen-glicol, carboxi-metil-celulosa y polioxilglicerido.
JP2019524772A (ja) * 2016-08-02 2019-09-05 ヴァージニア コモンウェルス ユニバーシティ ５−コレステン−３，２５−ジオール，３−サルフェート（２５ｈｃ３ｓ）又は薬学的に許容される塩及び少なくとも１種の環状オリゴ糖を含む組成物

Also Published As

Publication number Publication date
CN114555044A (zh) 2022-05-27
TW202128184A (zh) 2021-08-01
MX2022003778A (es) 2022-04-25
EP4037650A1 (en) 2022-08-10
IL291287A (en) 2022-05-01
JP2022549621A (ja) 2022-11-28
EP4037650A4 (en) 2023-10-18
CA3155422A1 (en) 2021-04-08
WO2021067297A1 (en) 2021-04-08
KR20220075329A (ko) 2022-06-08
US20220378802A1 (en) 2022-12-01
AU2020357818A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
BR112019002275A2 (pt) inibidores aminopirimidina de ssaos
BR112018070676A2 (pt) construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos
EA201791675A1 (ru) Человеческие антитела к гликопротеину вируса эбола
EA201890731A1 (ru) Модуляторы корового белка гепатита b
EA201891983A1 (ru) Комбинированная терапия антителами к cd73
BR112018007046A2 (pt) anticorpo isolado ou fragmento de ligação a antígeno, composição farmacêutica, molécula de polinucleotídeo isolado, vetor, célula, e, métodos para inibir o crescimento de um tumor ou de uma célula tumoral e para tratar uma doença ou distúrbio.
EA202190485A1 (ru) Соединения, модулирующие fxr (nr1h4)
EA201991862A1 (ru) Композиции и способы, предназначенные для лечения гемоглобинопатий
BR112016016207A2 (pt) Anticorpo anti-pd-l1 isolado ou fragmento de ligação ao antígeno do mesmo, seu método de produção, composição farmacêutica, molécula de polinucleotídeo isolada, vetor, célula, e uso dos mesmos
EA201892480A1 (ru) Соединения, модулирующие fxr (nr1h4)
BR112016029318A2 (pt) tratamento de mielomas
MX2017015811A (es) Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
BR112016000975A8 (pt) esteróides neuroativos, composições os compreendendo e uso dos mesmos
BR112016016699A2 (pt) Anticorpos humanos para pd-1
WO2016029073A3 (en) Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
MX2024000780A (es) Anticuerpo anti-pd-1 para usarse en el tratamiento de cancer de pulmon.
BR112022003956A2 (pt) Anticorpos anti-cd73
EA201891399A1 (ru) Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний
CR20170080A (es) Terapia de combinación para alzheimer que usa anticuerpos anti-n3pglu abeta+inhibidor de a bace
BR112022009317A2 (pt) Anticorpos de cd73 biparatópicos
BR112021014699A2 (pt) Métodos de tratamento de mieloma múltiplo
BR112018073945A2 (pt) métodos para tratamento de miastenia grave generalizada refratária
BR112015021483A2 (pt) arginina deiminase com reduzida reatividade cruzada para anticorpos adi-peg 20 para o tratamento do câncer
EA201990988A1 (ru) Антитела против chikv и пути их применения
BR112022008183A2 (pt) Formas de sal de um receptor de c5a de componente do complemento